Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular...

Area of Science:

• Cardiovascular science
• Metabolic disease research
• Inflammation and immunology

Background:

• Cardiovascular disease (CVD) is a major global health concern, with atherosclerosis as its primary pathology.
• Atherosclerosis development is linked to metabolic risk factors like dyslipidemia and obesity.
• Systemic inflammation, hypercholesterolemia, and obesity are interconnected, contributing to endothelial dysfunction.

Approach:

• This review synthesizes current literature on the relationship between hypercholesterolemia, obesity, systemic inflammation, and endothelial dysfunction.
• It examines the earliest stages of atherogenesis, including leukocyte infiltration into the arterial wall.
• The review discusses current and emerging pharmacological therapies for metabolic disorders.

Key Points:

• Hypercholesterolemia and obesity are associated with low-grade systemic inflammation.
• Endothelial dysfunction, a proinflammatory state, is linked to both metabolic disorders and early atherogenesis.
• Therapeutic strategies targeting metabolic abnormalities may impact systemic inflammation and cardiovascular risk.

Conclusions:

• Understanding the interplay between metabolic disorders, inflammation, and endothelial dysfunction is crucial for CVD prevention.
• Pharmacological interventions for hypercholesterolemia and obesity show promise in mitigating associated inflammatory processes.
• Further research is needed to fully elucidate the cardiovascular benefits of these therapies.